Phase Separation and Prion‐Like Aggregation of p53 Family Tumor Suppressors: From Protein Evolution to Cancer Treatment
Jerson L. Silva(National Institute of Science and Technology for Structural Biology and Bioimaging), Guilherme A. P. de Oliveira(Universidade Federal do Rio de Janeiro), Julia Quarti(Universidade Federal do Rio de Janeiro), Luciana P. Rangel(Universidade Federal do Rio de Janeiro), Giulia D. S. Ferretti(Medical University of South Carolina), Mayra A. Marques(Universidade Federal do Rio de Janeiro), Gileno dos S. de Sousa(Universidade Federal do Rio de Janeiro), Michelle F. Mota(Universidade Federal do Rio de Janeiro), Tuane C. R. G. Vieira(Universidade Federal do Rio de Janeiro), Elaine C. Petronilho(Universidade Federal do Rio de Janeiro), Guilherme C. de Andrade(Universidade Federal do Rio de Janeiro), Francisca Hildemagna Guedes-da-Silva(Universidade Federal do Rio de Janeiro)
Cited by 10
Related Papers
Ligand Binding and Hydration in Protein Misfolding: Insights from Studies of Prion and p53 Tumor Suppressor Proteins
|Accounts of Chemical Research|2009|110
Phase separation of p53 precedes aggregation and is affected by oncogenic mutations and ligands
|Chemical Science|2021|108
p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells
|Journal of Biological Chemistry|2019|86
Oncogenic Gain of Function in Glioblastoma Is Linked to Mutant p53 Amyloid Oligomers
|iScience|2020|82
Targeting Biomolecular Condensation and Protein Aggregation against Cancer
|Chemical Reviews|2023|78